Resources Repository
-
ExerciseNone, Teaching Resource 2024Lab: Autoimmune Encephalitis Decision Tree Model
This tutorial walks through the development of a decision tree model based on a published …
This tutorial walks through the development of a decision tree model based on a published cost-effectiveness analysis of routine screening for autoimmune encephalitis in patients with first-episode psychosis in the United States based on the published article: Ross EL, Becker JE, Linnoila JJ, Soeteman DI. Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients with First-Episode Psychosis in the United States. J Clin Psychiatry 2020; 82 (1): 19m13168. The tutorial describes how to build the…
Mathematical Models | Cost-Effectiveness Analysis | Decision Analysis | Clinical Care | Health/Medicine | Graduate | Doctoral | Professional -
Tutorial/PrimerPublication, Teaching Resource 2024Tutorial: Building Decision Trees
This tutorial illustrates the basic steps needed to develop decision trees in Amua using a …
This tutorial illustrates the basic steps needed to develop decision trees in Amua using a disease screening example. It details the process of how to build the structure of a decision tree, parameterize the model with probabilities and relevant outcomes (i.e., life expectancy), evaluate three alternative screening strategies in a baseline scenario, and perform one-way sensitivity analyses to assess the robustness of the results to different parameter values. Amua, the Swahili word meaning “decide”/“solve”, is…
Probability/Bayes | Mathematical Models | Decision Analysis | Clinical Care | Health/Medicine | Graduate | Doctoral | Professional -
ExerciseNone, Teaching Resource 2024Lab: Giant Cell Arteritis Decision Tree Model
This tutorial walks through the development of a decision tree model focused on Giant Cell …
This tutorial walks through the development of a decision tree model focused on Giant Cell Arteritis. It describes how to build the model structure, assign probabilities and outcomes based on imperfect test characteristics and epidemiologic estimates, evaluate alternative treatment strategies, and conduct one-way sensitivity analyses to assess which model parameters may impact the optimal treatment choice. Amua, the Swahili word meaning “decide”/“solve”, is an open source modeling framework and probabilistic programming language for decision analysis…
Probability/Bayes | Mathematical Models | Decision Analysis | Clinical Care | Health/Medicine | Graduate | Doctoral | Professional -
ArticlePublication 2022WHO ACTION-I Trial in Low Resource Countries
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk …
This study evaluated the cost-effectiveness of dexamethasone administration in dexamethasone in pregnant women at risk of early preterm birth using data from a multicentre, randomized, placebo-controlled trial in Bangladesh, India, Kenya, Nigeria, and Pakistan. Primary cost data were collected in 28 hospitals across the 5 countries. A decision tree model was used to compare dexamethasone treatment to no intervention from a health-care sector perspective. Administration of dexamethasone averted 38 neonatal deaths per 1000 woman–baby units…
Mathematical Models | Cost-Effectiveness Analysis | Health Outcomes | Clinical Care | Maternal/Reproductive Health | Child/Nutrition | Global | Sub-Saharan Africa | Asia & Pacific -
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Cervical Cancer Models
This resource pack, curated by the Center for Health Decision Science, is a collection of …
This resource pack, curated by the Center for Health Decision Science, is a collection of models of HPV-related cervical cancer, differing in design, structure and features based on analytic objectives. In many ways, HPV and its related diseases represent a prototypical public health problem given the communicable and non-communicable nature of disease, opportunities for intervention along the entire disease spectrum (e.g., primary and secondary prevention, diagnosis, treatment), the varied ages at which interventions are targeted…
Dynamic Simulation | Mathematical Models | Cost-Effectiveness Analysis | Clinical Care | State-Transition | Dynamic Transmission | Microsimulation | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Mathematical Models | Cost-Effectiveness Analysis | Health Outcomes | Clinical Care | Preferences/Values | Costing Methods | Infectious Diseases | Culture/Society | Health/Medicine | Science/Technology | North America | Europe -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Outcomes | Clinical Care | Costing Methods | Infectious Diseases | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Mathematical Models | Cost-Effectiveness Analysis | Clinical Care | State-Transition | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Mathematical Models | Cost-Effectiveness Analysis | Clinical Care | Chronic Disease/Risk | North America